Search results

Research to determine the potential dose from long- lived radioactive substances at mining, legacy sites and nuclear facilities.

ANSTO has made a contribution to the successful NASA/JPL Ingenuity helicopter flight on Mars through instrument scientist, Dr Andrew Nelson, who was one of the many developers of the open-source software SciPy used in the flight.

ANSTO is proud to support calls for daring and innovative ideas to fight COVID-19 as part of the ACS online Flatten The Curve hackathon.

First paper from Bilby investigates the effects of inorganic ions on the self-assembly of lecithin

Detailed molecular structure of silver nanocrystals determined

Radiation testing of electronic components at ANTO could benefit the aviation industry, regulators and most importantly, passengers as solar radiation events increase.

Neutron Capture Enhanced Particle Therapy developed at ANSTO.

The Advanced Diffraction and Scattering beamlines (ADS-1 and ADS-2) are two independently operating, experimentally flexible beamlines that will use high-energy X-ray diffraction and imaging to characterise the structures of new materials and minerals.

Environmental scientist with a passion for fieldwork and a lifelong commitment to scientific excellence

In Australia and the Southeast Asia basin, the ANSTO facility offers a wide range of unique nuclear-beam techniques for cultural heritage research.

Researchers from ANSTO and NASA’s Jet Propulsion Laboratory have uncovered the likely mineral composition of Saturn’s largest moon, Titan, revealing a world of exotic organic crystals unlike any found on Earth.

indigenous Cultural Intellectual Property is a broader way of talking about First Peoples’ rights to their cultural heritage, traditional knowledge and cultural expressions.

Insights into the crystallisation process of twin crystals important for drug production.

Collaboration across the Tasman has enabled Australian and New Zealand researchers and scientists to shed light on a protein involved in diseases such as Parkinson’s disease, gastric cancer and melanoma.

ITRAX has now analysed more than a kilometre of cores since it became operational in 2012.